ORGANIX, INC.

Basic Information

240 SALEM ST
WOBURN, MA, 01801-

Company Profile

n/a

Additional Details

Field Value
DUNS: 161843057
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Pharmacological Suppression of Rod Opsin as Therapy for Retinitis Pigmentosa

    Amount: $289,823.00

    DESCRIPTION (provided by applicant): Metastasis of aggressive breast cancer is a devastating and ultimately fatal condition. The current first- line agents which are used to treat breast cancer metast ...

    SBIR Phase I 2013 Department of Health and Human Services
  2. Vaginal Tactile Imager for Pelvic Floor Biomechanical Assessment

    Amount: $279,256.00

    DESCRIPTION (provided by applicant): Chronic pain can result from various disease conditions and about 45% of the U. S. population seeks medical help for treatment of pain. Neuropathic pain is a type ...

    SBIR Phase I 2013 Department of Health and Human Services
  3. The first reversible radioligand for the hVMAT2 [3H]reserpine binding site

    Amount: $250,001.00

    DESCRIPTION (provided by applicant): Abuse of methamphetamine (MA) is a major health problem. About 10 million Americans have used MA at least once. Chronic MA use has far reaching health consequences ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Benzodiazepine Analogs as Novel Treatments for Catatonia

    Amount: $686,852.00

    DESCRIPTION (provided by applicant): Catatonia is a widespread and serious syndrome characterized by mutism, stupor, refusal to eat or drink, posturing, and hypokinesis, and affects a broad range of p ...

    SBIR Phase I 2011 Department of Health and Human Services
  5. CB2 Agonists for Treatment of Neuropathic Pain.

    Amount: $130,505.00

    DESCRIPTION (provided by applicant): Neuropathic pain is a type of chronic pain state caused by injury or disease to the nervous system. Annual medical spending due to pain has been estimated to be o ...

    SBIR Phase I 2008 Department of Health and Human Services
  6. Indole Analogs as Novel Appetite Suppressants

    Amount: $436,879.00

    DESCRIPTION (provided by applicant): Obesity affects millions of people in the U.S. and worldwide, and this disease has enormous health and economic consequences for our society. Existing treatments s ...

    SBIR Phase II 2007 Department of Health and Human Services
  7. Indole Analogs as Novel Treatments for OCD

    Amount: $1,464,920.00

    DESCRIPTION (provided by applicant): Obsessive Compulsive Disorder (OCD) is a serious mental illness that affects millions of people throughout the world. Existing therapies for OCD show limited effi ...

    SBIR Phase II 2006 Department of Health and Human Services
  8. Novel THC/Anandamide Hybrids as Appetite Suppressants

    Amount: $504,211.00

    Obesity has reached epidemic proportions and in a year about 300,000 people die of obesity-related diseases. Annual medical spending due to obesity and overweight is about $117 billion. There is an ur ...

    SBIR Phase I 2005 Department of Health and Human Services
  9. Indole Analogs as Novel Appetite Suppressants

    Amount: $559,580.00

    DESCRIPTION (provided by applicant): Obesity affects millions of people in the U.S. and worldwide, and this disease has enormous health and economic consequences for our society. Existing treatments s ...

    SBIR Phase I 2003 Department of Health and Human Services
  10. INDOLE ANALOGS AS NOVEL TREATMENTS FOR OCD

    Amount: $109,197.00

    Obsessive Compulsive Disorder (OCD) is a serious mental illness that affects millions of people throughout the world. Existing therapies for OCD show limited efficacy, can possess troubling side effec ...

    SBIR Phase I 2002 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government